CDC STACKS serves as an archival repository of CDC-published products including scientific findings, journal articles, guidelines, recommendations, or other public health information authored or co-authored by CDC or funded partners.
As a repository, CDC STACKS retains documents in their original published format to ensure public access to scientific information.
i
This Document Has Been Replaced By: Prevention and Control of Seasonal Influenza with Vaccines : Recommendations of the Advisory Committee on Immunization Practices — United States, 2017–18 Influenza Season
Superseded
This Document Has Been Replaced By: Prevention and Control of Seasonal Influenza with Vaccines : Recommendations of the Advisory Committee on Immunization Practices — United States, 2017–18 Influenza Season
Prevention and Control of Influenza : Recommendations of the Advisory Committee on Immunization Practices (ACIP)
-
July 29, 2005
-
-
Source: Morbidity and Mortality Weekly Report (MMWR): Recommendations and Reports, 2005; v. 54, no. 8
[PDF-594.94 KB]
Details:
-
Journal Article:Morbidity and Mortality Weekly Report (MMWR): Recommendations and Reports
-
Personal Author:
-
Corporate Authors:
-
Description:This report updates the 2004 recommendations by the Advisory Committee on Immunization Practices (ACIP) regarding the use of influenza vaccine and antiviral agents (CDC. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices [ACIP]. MMWR 2004;53[No. RR-6]:1–40). The 2005 recommendations include new or updated information regarding 1) vaccination of persons with conditions leading to compromise of the respiratory system; 2) vaccination of health-care workers; 3) clarification of the role of live, attenuated influenza vaccine (LAIV) in vaccine shortage situations; 4) the 2005–06 trivalent vaccine virus strains: A/California/7/2004 (H3N2)-like, A/New Caledonia/20/99 (H1N1)-like, and B/Shanghai/361/2002-like antigens (for the A/California/7/2004 [H3N2]-like antigen, manufacturers may use the antigenically equivalent A/New York/55/2004 virus, and for the B/Shanghai/361/2002-like antigen, manufacturers may use the antigenically equivalent B/Jilin/20/2003 virus or B/Jiangsu/10/2003 virus); and 5) the assessment of vaccine supply, timing of influenza vaccination, and prioritization of inactivated vaccine in shortage situations. A link to this report and other information can be accessed at http://www.cdc.gov/flu.
-
Content Notes:Includes bibliographical references (p. 31-40).
-
Subjects:
-
Source:
-
Series:
-
ISSN:1057-5987 (print);1545-8601 (digital);
-
Pubmed ID:16086456
-
Document Type:
-
Genre:
-
Pages in Document:44 pdf pages
-
Volume:54
-
Issue:8
-
Collection(s):
-
Main Document Checksum:
-
Download URL:
-
File Type: